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Summary
Objective: To describe the frequency, risk factors, and clinical features of bacillus Calmette-
Gue´rin (BCG) complications in HIV-infected children treated with highly active antiretroviral
therapy (HAART).
Methods: A retrospective study of children started on HAART between August 2002 and Novem-
ber 2004 was completed.
Results: Six percent (21/352; 95% CI 3.7—8.0%) developed BCG complications. All developed
ipsilateral axillary lymphadenitis; one child had suspected disseminated BCG infection. There
were 14 females;median age at start of HAARTwas 5months. BCGdisease developed amedian of 34
days after starting HAART. At baseline and 6 months into HAART, the median CD4 percentage and
log10 viral load were 12.3/6.1 and 23.9/4.5, respectively. Seventeen (81%) of the patients were
treatedwith either zidovudine or stavudine combinedwith lamivudine and ritonavir. Young age and
high baseline viral load were independent risk factors for development of BCG complications.
Mycobacterium bovis BCG was isolated in 70% of patients who underwent incision and drainage of
abscesses at the vaccination site or regional lymph nodes.
Conclusions: This study identified a high prevalence of BCG complications in children on HAART. A
clinical case definition of BCG immune reconstitution syndrome independent of laboratory
parameters for use in resource-limited settings should be developed.
# 2008 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.* Corresponding author. Tel.: +27 21 6585499; fax: +27 21 6891287.
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South Africa has one of the largest pediatric HIVepidemics. In
mid-2006 the Medical Research Council of South Africa esti-
mated that there were approximately 300 000 HIV-infected
children under 15 years of age living in the country.1 An
increasing number of infected children have been com-
menced on highly active antiretroviral therapy (HAART);
by mid-2006 more than 21 000 children were on HAART.2
The bacillus Calmette—Gue´rin (BCG) vaccine contains a
live attenuated strain of Mycobacterium bovis. South Africa
has administered routine neonatal BCG vaccination since
1974. Between July and December 2000, the route of admin-
istration was changed from percutaneous to intradermal. At
the same time, the BCG strain was changed from Tokyo 172 to
Danish 1331 (Statens Institut, Copenhagen, Denmark).3 The
World Health Organization (WHO) recommends that HIV-
infected children should not receive BCG vaccination.4 In
practice, HIV DNA PCR testing is rarely performed during the
first few weeks of life and virtually all newborns, irrespective
of their HIV status, receive BCG vaccination in South Africa.
The spectrum of adverse events after BCG vaccination
includes persistent ulceration and discharge from the vacci-
nation site, regional lymphadenitis with or without suppura-
tion and/or fistulation, and disseminated BCG infection.5,6
Transition to intradermal administration in South Africa was
associated with a transient increase in the frequency of
adverse events, most likely related to the technique of
administration.7 Publications have recently started describ-
ing the spectrum of BCG adverse events in the setting of HIV
infection.8—14 BCG vaccination significantly increases the risk
for disseminated infection.9,10 Vaccination site abscess for-
mation and/or regional suppurative adenitis after the com-
mencement of HAART have been documented in several
reports.8,11—14 In this study, we describe the prevalence of
and risk factors for BCG complications in HIV-infected chil-
dren after starting HAART.
Methods
Patients
Between August 1, 2002 and November 30, 2004, 352 children
were enrolled in a public sector antiretroviral treatment
program at the Red Cross Children’s Hospital in Cape Town,
South Africa. The indications for starting HAART concurred
with existing WHO recommendations for resource-limited
settings.15 At enrolment, clinical and laboratory evaluation
included CD4+ lymphocyte count and percentage and HIV-1
RNA PCR (viral load) measurement. All children commencing
HAART attend our clinic prior to starting treatment, two
weeks after starting treatment, monthly for 6 months, and
1—3 monthly thereafter to monitor clinical progress and to
identify adverse events. The monitoring plan included 6-
monthly CD4 count and percentage, and viral load.
Regional BCG disease was defined as persistent ulceration,
abscess or fistula limited to the BCG vaccination site (intra-
dermal injection into skin overlying right deltoid muscle), or
enlarged or suppurative lymphadenopathy of the right axilla.
Progressive regional disease was defined as enlarged or
suppurative lymphadenopathy with or without fistula forma-tion, extending beyond the right axilla (e.g., to the ipsilat-
eral supraclavicular or cervical lymph nodes). Suspected
disseminated BCG disease was defined as identification of
M. bovis BCG from suppurative regional lymphadenitis
and gastric lavage samples in the same patient with a com-
patible clinical syndrome.6,16 However, not all patients who
underwent percutaneous aspiration or surgical drainage of
abscesses had gastric lavage specimens sent for mycobacter-
ial culture. Mycobacterial blood or bone marrow cultures
were not routinely performed. A multiplex PCR method was
used to differentiate M. bovis BCG and other members of the
M. tuberculosis complex following culture of pus obtained
from suppurative lymphadenitis or abscesses.17
Data collected and analyzed included: patient demo-
graphics, baseline CD4+ lymphocyte count and percentage
measured by the PanLeucogating method,18 viral load mea-
sured by commercial assay (Nuclisens; bioMe´rieux, Boxtel,
the Netherlands), date of starting HAART, HAART regimen,
date that the BCG complication was first recorded by the
attending doctor, nature of the BCG complication, manage-
ment including surgical drainage of abscesses, and anti-
mycobacterial chemotherapy. Limitation of resources pre-
vented routine CD4 and viral load measurement at the time
that the BCG complications presented. Weight-for-age Z-
score (WAZ) was calculated using EpiInfo 2000, version 1.0
(Division of Surveillance and Epidemiology, CDC, Atlanta, GA,
USA). Cutaneous delayed-type hypersensitivity (DTH)
response to mycobacterial antigens (tuberculin skin testing)
was not routinely performed prior to starting HAARTor at the
time that the BCG complications presented. Photographs of
some of the lesions were taken with the consent of parents or
legal guardians of children. Ethics approval was obtained
from the Research Ethics Committee of the University of
Cape Town to analyze aspects of the antiretroviral treatment
program at the Red Cross Children’s Hospital, Cape Town
(reference number: 261/2002).
Statistical analysis
Data were analyzed with STATA version 8.0 (Stata Corp.,
College Station, TX, USA). The 95% confidence interval (CI)
for a binomial proportion was used to estimate the frequency
of BCG complications. Baseline characteristics of children
who did and did not develop BCG adverse events were
compared using the two-sample Wilcoxon rank sum
(Mann—Whitney) test for non-parametric continuous vari-
ables and the Chi-square or Fisher’s exact tests for catego-
rical data. Multiple logistic regression analysis using a
stepwise backward elimination procedure was performed
to find the best predictive model for developing a BCG
reaction. Comparison of baseline and 6-month characteris-
tics of children who developed BCG reactions and in whom
results at both time points were available were done using
paired t-test or Wilcoxon rank sign test for normally and non-
normally distributed data, respectively.
Results
Twenty-one out of a total of 352 (6%; 95% CI 3.7—8.0%)
children starting HAART during the study period developed
BCG complications. There were 14 females and seven males,
BCG complications in children on HAART e101and the median age (interquartile range) at start of HAART
was 5 months (3.8—8.5 months). Prior to commencing HAART,
the median CD4+ lymphocyte count (109/l) (IQR) was 0.42
cells (0.17—0.86), the median CD4+ lymphocyte percentage
(IQR) was 12.3 (8.8—16.3), and the HIV-1 log10 viral load (IQR)
was 6.1 (5.8—6.7). In 17 of the 21 patients (81%) the first-line
HAART regimen comprised either zidovudine or stavudine
combined with lamivudine and ritonavir. Other antiretroviral
regimens included stavudine, lamivudine, and efavirenz (2);
stavudine, lamivudine, and nevirapine (1); zidovudine, lami-
vudine, and lopinavir—ritonavir (1).
Baseline risk factors for developing BCG
complications
Baseline clinical, immunological, and virological data are
shown in Table 1. The baseline CD4+ lymphocyte count,
CD4+ percentage, and viral load were available for 345
(98%), 338 (96%), and 311 (88%) children, respectively.
Children who developed BCG complications were younger
at the start of HAART (p < 0.001) and had a higher HIV-1 log10
viral load (p = 0.001) than those who did not. There was no
significant difference in CD4+ lymphocyte count or percen-
tage. There was a non-significant trend towards a greater
number of BCG adverse events in female patients (p = 0.155).
BCG complications were more frequent in children whose
HAARTregimen included a protease inhibitor (PI) ( p = 0.001).
However, younger children were far more likely to be treated
with a PI-containing regimen ( p < 0.001) due to the lack of
availability of non-nucleoside reverse transcriptase inhibi-
tors in suitable formulations, and the desire to avoid using
nevirapine in those children exposed to perinatal nevirapine.
The apparent association with a PI-containing regimen dis-
appeared once the effect of age had been controlled.
Since the majority (17/21; 81%) of BCG complications
occurred in children aged 9 months or younger, a separate
analysis was performed on this subset. Within this group of
children, BCG complications occurred more frequently in
female infants ( p = 0.036), and there was a trend towards
lower baseline CD4+ lymphocyte counts ( p = 0.104).
In all the children (N = 352), the best predictive model for
developing BCG complications included age and log10 viral
load (Table 2). Younger children were significantly more atTable 1 Baseline demographic data (univariate analysis)
Characteristic No BCG complication (N = 33
Gender
Male 179 (96.2%)
Female 152 (91.6%)
Age (months) 27 (9—55) (N = 330)a
CD4+ cells (%) 12.0 (7—18) (N = 318)a
CD4+ cell count ( 109/l) 0.46 (0.21—0.85) (N = 325
Log viral load 5.6 (5.1—6.1) (N = 293)a
PI-containing regimen
No 173 (98.3%)
Yes 158 (89.8%)
Data are expressed as n (%) or median (interquartile range).
BCG, bacillus Calmette—Gue´rin; PI, protease inhibitor.
a Number of patients for whom data were available.risk with a 5.1% (95% CI 0.90—0.99) reduction in risk for each
additional month of age. The adjusted odds ratio (OR) for
every 1-unit increase in baseline log10 viral loadwas 2.93 (95%
CI 1.15—7.49). Gender was included in the model because of
the trend towards a greater incidence of BCG adverse events
among female patients, although this did not achieve sig-
nificance (OR 2.66, 95% CI 0.91—7.82).
A separate multivariate model was determined for chil-
dren aged 9 months and younger. There was no effect of age
within this group; however higher viral load was an important
predictor of developing complications (OR 3.29, 95% CI 1.01—
10.79). This was not apparent in the univariate analysis.
There was a non-significant trend towards a reduced like-
lihood of developing BCG complications in children with a
higher baseline CD4+ lymphocyte count (OR 0.21, 95% CI
0.04—1.28 for every additional 1  109cells/l). There were
also more BCG adverse events in females (OR 3.65, 95% CI
0.92—14.49).
Response to HAART in children with BCG
complications
The CD4+ lymphocyte percent and count, log10 viral load,
and WAZ after 6 months of HAARTwere analyzed in 17 (81%),
16 (76%), and 19 (90%) of the children experiencing BCG
complications, respectively (Table 3). Themedian gain (IQR)
in CD4+ lymphocyte count was 0.60  109/l (0.25—0.98)
and percentage was 8.09 (2.82—12.85). The median reduc-
tion (IQR) in log10 viral load was 2.17 (3.60—1.97). In two
children the CD4+ percentage decreased (by 5.25 percen-
tage points in one andby 2.07 percentage points in the other)
and in one child the CD4+ lymphocyte count decreased by
73  109 cells/l after 6months on HAART. In two children the
viral load increased after 6 months on HAART. In three
children, baseline or 6-month laboratory tests were not
performed and a further two children were lost to follow-
up after developing BCG complications.
Clinical features of BCG complications
The 21 children presented to hospital with BCG complications
a median (IQR) of 34 (15—60) days after starting HAART. All 211) BCG complication (N = 21) p-Value
7 (3.8%) 0.065
14 (8.4%)
5 (3.8—8.5) (N = 21)a <0.001
12.3 (8.8—16.3) (N = 20)a 0.55
)a 0.42 (0.17—0.86) (N = 20)a 0.76
6.1 (5.8—6.7) (N = 18)a 0.001
3 (1.7%) 0.001
18 (10.2%)
Table 2 Baseline demographic data (multivariate analysis)
Factor Adjusted OR (95% CI)
Age 0.95 (0.90—0.99)
Log viral load 2.93 (1.15—7.49)
Female gender 2.66 (0.91—7.82)
OR, odds ratio; CI, confidence interval.
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e102 J.J. Nuttall et al.children had abnormally enlarged right axillary lymph nodes
with or without suppuration (regional disease). Three (14%)
children first presented to hospital following spontaneous
discharge of pus from right axillary abscesses. Five children
had new ulceration or abscess formation at the BCG vaccina-
tion site (right deltoid). In addition to right axillary
abscesses, two (10%) children developed abscesses in the
ipsilateral supraclavicular and lower cervical regions (pro-
gressive regional disease) (Figure 1).
Mycobacterial culture of material obtained from
abscesses at the vaccination site, suppurative regional lymph
nodes, or gastric lavage specimens, was performed in 10 of
the 21 (48%) patients. Seven (70%) of these 10 cases had
positive cultures forM. boviswith further identification ofM.
bovis BCG by PCR; in two cases themycobacterial culture was
contaminated by bacterial overgrowth, and in one case the
mycobacterial culture was negative. Sensitivity testing was
performed on three of the sevenM. bovis BCG isolates and all
three were sensitive to rifampin and isoniazid.
One of the 21 children had previously experienced per-
sistent vaccine site ulceration and right axillary lymphade-
nitis following BCG vaccination prior to initiation of HAART.
After starting HAART, this patient presented with sponta-
neous rupture of an abscess in the right axilla.
In one patient with failure to thrive and hepatospleno-
megaly, M. bovis BCG was isolated from pus aspirated from a
right axillary abscess as well as from two gastric lavage
samples collected on different days during a hospital admis-
sion with fever and suspected septicemia. This patient was
suspected of having disseminated BCG disease. However, the
diagnosis was not confirmed by the culture of the organism
from blood or deep tissue biopsies.Ta
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Figure 1 BCG vaccine-induced complication presenting 34
days after starting HAART: ulceration at BCG vaccination site
(right deltoid) and abscess formation at right axillary lymph
nodes and supraclavicular region.
Table 4 Management of children with BCG complications
(N = 21)
Management Number of
children (%)
Aspiration/incision and drainage
of abscess only
9 (43)
Anti-mycobacterial chemotherapy only 4 (19)
Surgical and medical management 6 (29)
Monitoring and follow-up only 8 (38)
BCG, bacillus Calmette—Gue´rin.
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Treatment of BCG complications was not standardized.
Nine (43%) children underwent aspiration or formal incision
and drainage of suppurative regional lymphadenitis. Six of
these nine children also received anti-mycobacterial che-
motherapy. Four children were treated with anti-mycobacter-
ial chemotherapy and no surgical intervention. In eight (38%)
children there was no surgical or medical intervention and
the inflammatory swellings were closely monitored at
regular intervals (Table 4). Anti-mycobacterial chemotherapy
included a combination of rifampin, isoniazid, and ethiona-
mide (n = 10); one child developed elevated liver enzymes and
treatment was changed to a combination of isoniazid, ethio-
namide, and ofloxacin. One child was already receiving treat-
ment for pulmonary tuberculosis with rifampin, isoniazid, and
pyrazinamide for 3 months at the time that he developed the
BCG complication, and this treatment was continued. There
were no deaths attributable to BCG disease.
Discussion
The present study suggests that approximately 6% of HIV-
infected children who receive intradermal BCG vaccination
at birth may develop clinically significant BCG complications
after starting HAART. The narrow 95% CI of 3.7—8.0% for a
sample size of 352 children indicates that this is likely to be a
relatively accurate estimate. A previous study reported that
3.1% of nearly 10 000 children examined, developed adverse
events following BCG vaccination with the Danish 1331 BCG
vaccine during the first few months of life. In that study
the HIV status of the children was not established. Transition
from percutaneous to intradermal route of administration
may have been in part responsible for the relatively
high prevalence of BCG complications in that study. Most
of the affected children developed injection-site abscesses
(41.0%), site oozing (36.3%), or lymphadenopathy (18%).7 In
the present study, none of the BCG complications were
limited to the vaccination site. All 21 children developed
significant axillary lymphadenitis, three (14%) children pre-
sented with spontaneous rupture of axillary abscesses, two
developed progressive regional disease with abscesses in the
supraclavicular and cervical lymph nodes (Figure 1), and one
had presumed disseminated BCG disease, suggesting that
BCG complications in HIV-infected children are generally
more severe. This deduction is supported by previous studies
documenting high rates of disseminated BCG disease among
HIV-infected children.9,10In the face of mounting evidence of increased risk of
serious BCG complications in HIV-infected children and the
absence of studies evaluating the protective benefit of BCG in
HIV-infected children, in May 2007 the Global Advisory Com-
mittee on Vaccine Safety (GACVS) advised the WHO that the
benefits of potentially preventing severe tuberculosis are
outweighed by the risks associated with the use of BCG
vaccine. Children who are known to be HIV-infected, even
if asymptomatic, should no longer be immunized with BCG
vaccine. Where HIV testing is possible, BCG immunization
should be deferred until the HIV status of the infant has been
established, and should only be administered to HIV-unin-
fected infants.4
The temporal relationship between introducing HAART
and the onset of BCG complications suggests that most of
these adverse events are manifestations of the immune
reconstitution inflammatory syndrome (IRIS). BCG complica-
tions presented amedian of 34 days after starting HAART, and
all except one child presented within 90 days after starting
HAART. IRIS due to pathogens or opportunistic organisms is
believed to be a consequence of the restoration of pathogen-
specific immune responses in HIV-infected patients during the
first months of HAART. The observed clinical deterioration
(infectious disease complication) may represent a response
to high antigen burden, excessive response of a recovering
immune system, exacerbated pro-inflammatory cytokine
response, or a dysregulated immune response due to the
inability to generate regulatory mediators.19 Evidence for
early recovery of mycobacterial-specific immunity in chil-
dren previously vaccinated with neonatal BCG and exposed to
Mycobacterium tuberculosis was demonstrated in a recent
study.20
Reports of BCG complications occurring in HIV-infected
children not receiving HAART have predominantly described
localized diseasemanifesting as ulceration of the vaccine site
with or without ipsilateral axillary lymphadenitis, and less
frequently disseminated forms of disease.8,9 In keeping with
the few other reports in themedical literature describing IRIS
due to BCG,11—13 the children in this study all developed
ipsilateral axillary or extra-axillary lymphadenitis character-
ized by a marked local inflammatory response and tendency
for rapid progression to suppuration. These features may be
important elements of a clinical case definition of BCG IRIS.
We also identified one suspected case of disseminated BCG
disease presenting as IRIS. The incidence of disseminated
BCG disease presenting after commencement of HAART in
children is not known.
Diagnosis of IRIS due to infectious organisms is dependent
on documenting the infectious complication and demonstrat-
ing concomitant virological suppression and immune restora-
tion (an increasing CD4 count or percentage). Current case
definitions do not include a demonstration of pathogen-
specific immune recovery.11,12 In routine clinical practice
in high HIV-prevalence settings, resource constraints usually
preclude the performance of frequent viral load and CD4
measurements. Therefore, as in the present study, viral load
and CD4 measurements are rarely performed at the time of
onset of the BCG complication.
Prior to starting HAART, the median CD4 count
(0.42  109/l) and percentage (12.3%) of children who
developed BCG complications indicated severe immuno-
suppression. There was no association between the risk of
e104 J.J. Nuttall et al.developing BCG complications and CD4 count in the cohort.
In children aged 9months and younger inwhom81% of events
occurred, there was a non-significant trend towards a
greater likelihood of developing BCG complications in those
with lower baseline CD4 counts ( p = 0.104). The small total
number of children in this group (n = 99) may account for the
failure to show statistical significance. Children with higher
log viral load values prior to starting HAART, indicating more
rapidly advancing HIV disease, were more likely to develop
BCG complications ( p = 0.001). Young age was an additional
independent risk factor for BCG complications after starting
HAART.
Due to cost considerations, we were limited to measuring
CD4 count and viral load prior to starting HAART and there-
after at 6-monthly intervals. Measurements were not rou-
tinely performed at the time that BCG complications
developed. Comparison of baseline and 6-month CD4 counts,
viral loads, and WAZ indicated that the majority of children
with BCG complications experienced significant improve-
ment after 6 months of HAART, supporting the diagnosis of
BCG IRIS. One 7-month old infant who presented with spon-
taneous discharge of pus from an axillary abscess (from
which M. bovis BCG was isolated) 14 days after starting
HAART, had additional laboratory measurements performed
at 6 and 12 weeks on HAART. In this child, the CD4 count had
more than doubled after 6 weeks on HAART (0.171  109/l at
baseline; 0.491  109/l at 6weeks), and viral load decreased
by 2.8 log by 6weeks andwas<400 copies/ml by 12weeks on
HAART. This improvement in immune function and virologi-
cal indices strongly suggests that the suppurative BCG lym-
phadenitis was caused by IRIS. Deterioration in clinical and
laboratory parameters after 6 months on HAART in a few
children did not necessarily exclude IRIS as a cause for their
BCG complications. Deterioration several months after the
onset of the BCG complication may have been caused by a
number of factors including HIV disease progression as a
result of BCG disease, pharmacokinetic interaction between
rifampin and HAARTresulting in sub-therapeutic serum con-
centrations of antiretroviral drugs and treatment failure,
poor adherence to HAART, and development of HIV resistant
mutations.
There was no consistency in the treatment of the children
in the present study. Suspected or proven disseminated BCG
disease should be treated with anti-mycobacterial agents,
although the outcome with underlying cellular immunodefi-
ciency is frequently poor.21 Our patient with suspected dis-
seminated BCG disease developing after starting HAART
responded well to anti-mycobacterial therapy. Whether local
or regional BCG complications in children on HAART should
routinely receive anti-mycobacterial therapy is unre-
solved.8,22 This question requires interrogation through a
randomized control trial. Local surgical intervention is prob-
ably required for severe complications particularly for fluc-
tuant adenitis, fistulation, and possibly for lymph nodes
>1.5 cm in diameter. However, optimal surgical approaches
require further investigation.14
This study has certain important limitations. It was hos-
pital-based, which may have resulted in increased identifica-
tion and reporting of adverse events by both caregivers of the
children and clinicians, and thereby an overestimate of the
true incidence of BCG adverse events occurring in children
after starting HAARTacross the whole community. The retro-spective nature of the study means that there was no
standardized system for reporting, investigating, or mana-
ging BCG adverse events and this limits the ability to analyze
diagnostic approaches and outcomes.
Despite these inherent limitations, we recommend that
HIV-infected infants and young children who received
BCG vaccination prior to commencing HAART should be
closely monitored for BCG complications particularly during
the initial 3—6 months on treatment. Rapidly-enlarging or
fluctuant regional lymphadenitis should be managed with
aspiration or surgical incision and drainage.8,14,22 Mycobac-
terial culture of pus obtained from lymph nodes, as well as
mycobacterial blood culture if available, followed by differ-
entiation of M. bovis BCG from M. tuberculosis complex,
should ideally be performed to confirm the diagnosis and
identify disseminated BCG infection. Suspected or con-
firmed disseminated disease should be treated with anti-
mycobacterial chemotherapy. M. bovis BCG is inherently
resistant to pyrazinamide and this drug should not be used.21
Liver functions should be closely monitored. Pharmacoki-
netic interactions of rifampin with non-nucleoside reverse
transcriptase inhibitors and protease inhibitors may poten-
tially result in sub-therapeutic serum concentrations of
antiretroviral drugs that may lead to antiretroviral treat-
ment failure. The antiretroviral regimen should therefore be
reviewed and appropriately modified.
In conclusion, while contributing to information on the
prevalence and risk factors for BCG complications in HIV-
infected children on HAART, this study has identified the need
for a clinical case definition of BCG IRIS independent of
laboratory parameters for use in resource-limited settings.
Furthermore, the role of inexpensive measures to treat the
majority of local or regional complications should be rigor-
ously evaluated.
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